olaparib bio-better (NXP004) / Nuformix - LARVOL DELTA

"#nfx @AstraZeneca interest in nxp004? One would think so https://t.co/RwUy5EkKrF" (@bullish7777)

Nuformix encouraged by pre-clinical data from IPF candidate (Proactiveinvestors) - "Nuformix PLC...said its NXP004 fibrosis programme in human idiopathic pulmonary fibrosis (IPF) had showed promise in a key area in early-stage pre-clinical trials....NXP004 showed a dose-dependent reduction in the secretion of these key components, Nuformix said. The data also suggests NXP004 compares favourably to current standard of care with regard to anti-fibrotic activity in this model....Nuformix said, adding the delivery of a full pre-clinical study data set is the next focus."

Preclinical • Idiopathic Pulmonary Fibrosis